导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 10.19% | 79/324 |
| 近一周 | -1.71% | 91/332 |
| 近一月 | -3.76% | 158/332 |
| 近一季 | -3.77% | 170/332 |
| 近半年 | 14.56% | 55/328 |
| 近一年 | 12.40% | 94/319 |
| 近两年 | 37.31% | 105/284 |
| 近三年 | 72.33% | 37/222 |
| 成立以来 | 278.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.05% 199/360 |
24.39% 62/366 |
- - |
- - |
| 2025 | 15.29% 227/358 |
-8.08% 270/340 |
16.38% 68/348 |
7.30% 224/354 |
0.45% 162/358 |
| 2024 | 24.69% 46/329 |
8.28% 64/280 |
7.73% 62/310 |
0.24% 238/318 |
6.63% 34/329 |
| 2023 | 52.84% 15/275 |
17.59% 37/205 |
20.14% 21/230 |
-3.64% 85/262 |
12.28% 54/276 |
| 2022 | -25.79% 122/201 |
-9.41% 84/153 |
-17.05% 126/164 |
0.94% 23/189 |
-2.17% 173/202 |
| 2021 | 22.21% 39/150 |
2.13% 133/312 |
8.78% 84/328 |
1.16% 44/358 |
8.75% 40/151 |
| 2020 | 33.64% 21/103 |
-10.25% 131/280 |
28.32% 54/295 |
8.02% 66/299 |
7.43% 164/305 |
| 2019 | 37.57% 10/88 |
13.42% 66/258 |
5.70% 29/268 |
3.83% 44/253 |
10.51% 62/266 |
| 2018 | 3.01% 11/79 |
- - |
- - |
- - |
-16.39% 183/241 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2946 | 31.47% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3488 | 29.79% |
| 汇添富恒生生物科技ETF(QDII) | 1.1245 | 29.24% |
| 南方恒生生物科技ETF(QDII) | 1.1400 | 29.08% |
| 广发道琼斯石油指数美元现汇A | 0.4638 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4557 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4568 | 27.33% |
| 南方恒生生物科技ETF发起联接(QDII)A | 1.2646 | 27.30% |
| 华夏恒生生物科技ETF发起式联接(QDII)C | 1.1472 | 27.25% |
| 汇添富恒生生物科技ETF发起式联接(QDII)C | 1.6358 | 27.22% |
| 易方达纳斯达克100ETF联接(QDII-LOF)A(人民币) VS. 建信富时100指数(QDII)人民币A(539003) |